Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives

Mariam Ismail, Noran Al-Gizey, Ebtesam Al-Najjar, Zaid Alabed, Nour Mustafa, Yazan Hamdaneh, Abdullah Esmail · 2026

Read Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives by Mariam Ismail, Noran Al-Gizey, Ebtesam Al-Najjar, Zaid Alabed, Nour Mustafa, Yazan Hamdaneh, Abdullah Esmail (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13598834.txt.

Description

Mariam Ismail and six colleagues review antibodies engineered to grab two targets at once, and their growing role against gut and liver cancers, in a 2026 paper. Most digestive cancers shrug off standard immune drugs, thanks to cold tumors and hostile surroundings.

Two-target antibodies can steer killer T cells onto cancer, block two brakes at once, or combine immune and blood-vessel attacks. One such drug, aimed at the HER2 growth signal, has already won approval, and many late-stage trials are running across bowel, stomach, liver, pancreas, and bile duct cancers. The review weighs formats, targets, patient selection markers, side effects, and factory hurdles. The authors see the class becoming a core piece of precision cancer care.

Catalog record

CREATORMariam Ismail, Noran Al-Gizey, Ebtesam Al-Najjar, Zaid Alabed, Nour Mustafa, Yazan Hamdaneh, Abdullah Esmail
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE130 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13598834

Browse the full library · About the Tower of Babel